virus as therapy against lymphoma and other cancers

[Guest guest]

About JX-594

Jennerex's lead product candidate, JX-594, is based on the vaccinia virus

strain which is uniquely suited to treat cancers. JX-594 is genetically

modified by deleting its thymidine kinase gene to enhance

cancer-selectivity. In addition, it has been armed with GM-CSF gene to

stimulate systemic anti-tumoral immune response in the context of product

replication and lysis of the infected cancer cells. It is designed to

destroy both injected and non-injected metastatic tumors. This virus was

engineered from the strain of vaccinia virus that is the basis for the

vaccine that has been used in hundreds of millions of people in vaccination

against smallpox.

Jennerex Publishes Clinical Trial Data With Lead Product JX-594

Demonstrating Efficacy Against Liver Cancer And Associated Hepatitis B Virus

http://www.medicalnewstoday.com/articles/115848.php

JX-594 is a targeted oncolytic poxvirus designed to selectively replicate in

and destroy cancer cells with cell-cycle abnormalities and epidermal growth

factor receptor (EGFR)-ras pathway activation.

http://www.ncbi.nlm.nih.gov/pubmed/18495536

Systemic Efficacy with Oncolytic Virus Therapeutics:

Clinical Proof-of-Concept and Future Directions

http://cancerres.aacrjournals.org/content/67/2/429.full.pdf

JX-594 Clinical trial - enrolling children with lymphoma

http://bit.ly/buxjIZ

Karl Schwartz

President, Patients Against Lymphoma

www.Lymphomation.org

Evidence-based information on lymphoma, independent of health industry

funding